Skip to content
Parakho

Viyash Scientific Ltd

NSE VIYASHBSE 512529viyash.com

Q1 FY27, unaudited

Revenue
₹946.36 Cr
Profit after tax
₹79.29 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations946.36+114.39%3,420.31
Other income8.31+114.73%43.55
Total income954.67+114.39%3,463.86
Employee benefit expense162.65+105.70%565.50
Finance costs12.51−11.65%69.21
Depreciation & amortisation61.77+308.26%233.64
Total expenses842.26+101.25%3,070.63
Profit before tax112.41+340.48%349.02
Tax expense33.12+316.60%124.37
Profit after tax79.29+351.28%224.65
Total comprehensive income72.95+47.91%331.55
Earnings per share
Earnings per share, basic₹1.51₹4.09
Earnings per share, diluted₹1.47₹4.01

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Viyash Scientific reported Q1 FY27 revenue of Rs. 946 crores, up about 20% year-on-year, with EBITDA of Rs. 205 crores and margin expanding to 21.6%. Profit after tax rose to Rs. 79 crores, more than double the prior year, while net debt fell to Rs. 86 crores with net debt to EBITDA at 0.1x. Management discussed the signed agreement to acquire BioForLife in Italy, growth across Animal Health and Human formulation businesses, and flat API revenue attributed to customer wait-and-watch behavior on raw material pricing.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 61 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.